Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. (MET) non‑management director Carla A. Harris acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After this transaction the reporting person beneficially owned 9,048 shares. The filing states these shares represent part of director retainer fees that were elected to be deferred under the MetLife Deferred Compensation Plan for Non‑Management Directors. The Form 4 was signed by an attorney‑in‑fact on behalf of the reporting person on 10/03/2025.
Laura J. Hay, a non‑management director of MetLife, Inc. (MET), reported a purchase of 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction, the reporting person beneficially owned 4,261 shares. The Form 4 notes these shares are part of the director retainer that the director elected to defer under the MetLife Deferred Compensation Plan for Non‑Management Directors. The filing was signed by an attorney‑in‑fact on 10/03/2025. The form contains no options or derivative transactions and no other changes to ownership were disclosed.
MetLife, Inc. director Diana McKenzie acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share under the company’s non‑management director compensation program. The filing states that a portion of non‑management director retainer fees are paid in common stock and that Ms. McKenzie elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non‑Management Directors. After this transaction she beneficially owns 22,757 shares, reported as direct ownership. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. The disclosure is limited to the director grant and deferral; no additional financial results, guidance, or other transactions are included in this filing.
MetLife, Inc. (MET) non-management director Christian Stephane Mumenthaler reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction he beneficially owned 1,458 shares. The filing states these shares were part of director retainer fees and were deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The report reflects a routine compensation-related equity grant and deferral by a board member.
The Form 4 shows that Mark A. Weinberger, a non‑management director of MetLife, Inc. (MET), received 534 shares of MetLife common stock as part of the company's director compensation plan on 10/01/2025. After this award, his beneficial ownership totaled 17,441 shares. The filing states these shares were issued under MetLife's practice of paying a portion of non‑management director retainer fees in common stock.
Robert Glenn Hubbard, a non-management director of MetLife, Inc. (MET), reported an acquisition of 916 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After this transaction, the filing shows 102,067 shares beneficially owned directly by the reporting person.
The filing notes these shares were issued as part of MetLife's non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
MetLife director Carlos M. Gutierrez acquired 534 shares of MetLife, Inc. common stock on 10/01/2025 as part of the company’s non-management director compensation program that pays a portion of retainer fees in common stock. After the purchase, Mr. Gutierrez directly owns 24,385 shares and indirectly holds 18,807 shares through the Carlos M. Gutierrez Trust. The transaction was reported on a Form 4 filed and signed via attorney-in-fact on 10/03/2025.
MetLife director William E. Kennard reported an acquisition of 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After the transaction, the reporting person beneficially owned 44,452 shares. The filing notes these shares were part of non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. Some shares are held indirectly through the MetLife Policyholder Trust, which holds shares allocated to eligible policyholders of a MetLife subsidiary.
Johnson Jeh C., a non-management director of MetLife, Inc. (MET), reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After the transaction the reporting person beneficially owns 7,372 shares. The shares were paid as part of non-management director retainer fees and the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025.
Denise M. Morrison, identified as a director of MetLife, Inc. (MET), reported a non-derivative acquisition of 534 shares of MetLife common stock on 10/01/2025. The shares were issued as part of MetLife's non-management director compensation and recorded with a price of $0 (retainer paid in stock). Following the transaction the reporting person beneficially owned 33,351 shares. The Form 4 filing was signed on 10/03/2025 by an attorney-in-fact. The disclosure states these shares represent a portion of the director retainer paid in company stock.